May 16th, 10:15 AM

UMMS Biomedical Data Assets & D3Health

Jomol Mathew
University of Massachusetts Medical School

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat

Part of the Health Information Technology Commons, and the Translational Medical Research Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

https://escholarship.umassmed.edu/cts_retreat/2017/program/6

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
UMMS Biomedical Data Assets & D3Health

Jomol Mathew, Ph.D.
May 15, 2017
Disclosures:

I have no actual or potential conflict of interest in relation to this program/presentation.
University of Massachusetts is Uniquely Positioned to be a Game Changer in Healthcare

- Pathways to Clinical Integration
- World-class Biomedical Research
- World-class Health Informatics
- Expertise in Digital Health & Sensors
- Ethnically Diverse Population In Central Mass
Patients generate useful data that is not available to health care providers.

We will break down barriers to integrate data & make it available for clinical decision making.
Our Clinical and Translational Research Data Ecosystem

Vision: Build an Integrative Clinical & Biospecimen Data Ecosystem to:

- Enable data driven research
- Enable translation of research findings to clinical care
- Make a difference in community and global health
Data Lake holds Clinical data from >2.5 Million patients representative of national diversity

- A rich source of data for studying chronic diseases (e.g. cardiovascular, diabetes)
- A useful tool to study genetic diseases (e.g. Cystic Fibrosis, Parkinson’s)
- A mechanism to link biosamples, molecular data & digital health data to clinical data
**D³Health: Integrating Biomedical Big Data, Analytics, & Decision Support**

1. **Data Collection**
   - Home monitoring of patient wellness and disease data; environmental data
   - Hospital EHR Data

2. **Data Lake**
   - Aggregation
   - Data Integration
   - Data from Remote/Sensors is integrated with clinical data

3. **Predictive Analytics**
   - Pattern Recognition
   - Artificial Intelligence
   - Algorithms
   - Knowledge is generated and actionable intervention points are identified

4. **Decision Support**
   - Knowledgebase with Actionable Intervention Points & Generation of Feedback Loops
   - Provider Feedback

- **Alerts**
  - Patient Alerts (e.g., changes in Transthoracic Bioimpedance)
  - Community Alerts (e.g., Infection outbreaks)
  - Targeted Clinical Trials
  - Intervention Alerts (e.g., Alter Medication)
  - More Effective Precision Therapy
  - Community Alerts (e.g., Infection outbreaks)
  - Provider Feedback

**Benefit Areas**
- RESEARCH
- EDUCATION
- CLINICAL CARE
Data Lake & D3Health will help us study Diseases...... Continuum of Care...... Continuous Learning Cycles...

What Treatment is Better for Me/My Patient?

- What causes this disease?
- Am I eligible for a new study?
- What are the treatment options?
- How do I compare to other patients?
- What is involved in the study?
- Is this condition genetically transferable?
- What are the potential adverse events for the new study?
- Why do some patients develop resistance to drugs?
- Why do some patients respond well/poor to specific drugs?
- Why does the disease progress faster for some patients?
- Are there sub-classes within this disease?
- Why does this patient compare to other patients?
- What is the best course of treatment?
- What is the biological underpinning of this disease?
- All there clinical trials targeting the specific genetic alterations found in this patient?
- Enables Researchers to get a list of patients who have consented to be contacted about upcoming studies

Expanding via
- Social media
- Special population resource center
- Direct to patient tools
- Recruiting via EHR once EPIC in place
**Data Ecosystem Components: OpenSpecimen for BioBanking**

**Single Shop for Biospecimens**
- Consent, collect & barcode
- Create derivatives & keep lineage
- Search & find
- Scan & distribute
- Link to clinical data in Data Lake & facilitate query and request of biospecimens from central biobanks (blood, tumor, microbiome)
Data Ecosystem Components: LabArchives for Collection & Management of Research Data

• Electronic Lab Notebook
• Enables easy access to data between lab members and collaborators
• Supports secure data trail (necessary for commercialization)

• ~ 300 Users are using LabArchives
Data Ecosystem Components: Synergist for Searching & Sharing Research Data

“Amazon” of Research data
- Catalog & Share Experimental Metadata
- Search and Discover Data & Collaborate
- Connect & Gain Insights
- Publish & Submit Data to External Data Banks
Data Ecosystem Components: OnCore Clinical Trials Management System

- A leading CTMS platform at Academic Medical Centers
- Integrates well with EPIC to
  - improve patient safety
  - Improve protocol compliance

- Went live on 10/21/16
- Onboarding complete by 07/01/2017
- EPIC Integration & go-live by 10/01/2017
Data Ecosystem Components: ONCORE Clinical Trials Management System & EPIC Integration

**EHR Primary Concerns:**

- Comprehensive management of a patient over time
  - Provide high-quality patient care
  - Patient safety
  - Clinical user efficiency and productivity
  - Research billing compliance (ability to separate clinical and research charges)

**CTMS Primary Concerns:**

- Comprehensive management of a study
  - Catalogs and tracks all clinical trial processes
  - Administrative activities e.g., budgeting, approval tracking, study design, randomization
  - Investigator compliance to administrative requirements
  - Subject protocol compliance
  - Direct reporting to sponsors

**Overlapping Needs:**
- Basic study information
- Patients associated with studies
- Research billing definition for study
ONCORE & EPIC Integration: Empowers Research & Care

- **Benefits for Researchers**
  - Achieve better recruitment for trials
  - Study Teams can track the subjects
  - Streamline collection of biospecimens

- **Benefits for Care Providers**
  - See that a patient is on a clinical trial in the banner
  - Get detailed information on the protocol
  - Identify clinical trials for patients

- **Benefits for Patients**
  - Get access to latest care especially when options are limited
Quantifying Patient Experiences: Patient Reported Outcomes

• Patient Reported Measures
  • Compendium describing PRM use across UMass community to facilitate prioritization of Epic build
  • Domain Examples: QoL, mental health, physical functioning, pain, PTSD, Tobacco/Alcohol/Drug use, etc.
  • Settings: Inpatient, Outpatient, ED
  • Populations: Adults, Pediatrics, Psych

• PRM administration
  • Currently Collected using: REDCap
  • Working with Epic Team to prioritize and build
Honest Broker: Connect Research & Clinical Data

- Enables integrative queries & extraction
- Avoid duplication of data
- Full Traceability & Accountability
- Compliance with HIPAA & regulations
Rules for Diving into the Data Lake: 
Data Access Policies and Processes @ UMMS

Key Policies:
- **Aggregate or De-identified data**: No IRB approval required
- **Protected Health Information (PHI)**: IRB approval required
- **BAA & Security clearance** required while engaging third-party vendors

Who Can Access Data:
- Research
  - Faculty: Instructor or above
  - Any member of a research team
- Quality & Operations
  - Administrators and staff at UMMHC or UMMS

How:

www.umassmed.edu/IT/CDP
37 structured interviewees in Germany, UK, Switzerland, and France indicated strong support for the proposed Electronic Health Records for Clinical Research (EHR4CR). All interviewees reported that using the platform for assessing feasibility would enhance the conduct of clinical trials and the majority also felt it would reduce workloads.
e.g. Botulinum Toxin for Pelvic Pain in Women With Endometriosis (NCT01553201)

- How does protocol design (exclusion/inclusion) impact recruitment?
- How can other sites selected for a multisite study?

**INCLUSION CRITERIA:**
- Female gender
- Age between 18 and 50
- History of endometriosis
- Persistent pelvic pain for at least 3 months
- Pelvic floor spasm
- Negative pregnancy test
- Willing to use reliable method of contraception for the month after botulinum toxin injection
- Willing and able to give informed consent
- Willing and able to comply with study requirements

**EXCLUSION CRITERIA:**
- Women with other causes of chronic pelvic pain including infectious, gastrointestinal, psychological disorders, fibromyalgia and chronic fatigue syndrome based on review of medical history within 1 year of first study visit*. 
- Untreated severe cervical dysplasia or other gynecologic condition within the past year based on medical record review*. 
- Significant abnormalities in the physical or laboratory examination including renal and liver function more than twice the normal range 
- Hysterectomy and bilateral salpingo-oophorectomy 
- Pregnancy 
- Lactation 
- Allergy to albumen or botulinum toxin 
- Presence of antibodies to botulinum toxin or loss of response to previous injections for any indication 
- A known neuromuscular junction disorder such as myasthenia gravis or Eaton-Lambert syndrome 
- History of urinary or fecal incontinence 
- Known pelvic prolapse

Coming Soon........CTSA Recruitment RFP – Improve Recruitment using Data Lake
UMMS: How to do Feasibility/Recruitment? Use DLR & Aggregate Search Capabilities

**INCLUSION CRITERIA:**
- Female gender
- Age between 18 and 50
- History of endometriosis

**EXCLUSION CRITERIA:**
- Fibromyalgia
- Cervical dysplasia
- Renal and liver function

**CURRENT**

Integrated Clinical-Genomic Searches
e.g. Female, Asian, NSCLC with EGFR mutations receiving Tarceva
- currently not on other trials
- consented for future contact

**Q2 2017**

Text continued
UMMS: How to do Feasibility/Recruitment? Use DLR & Explore De-identified Data

Comorbidities

Concomitant Medications

Labs
EHR Data Can Enable Comparative Effectiveness Studies

Leveraging EHR Data for Outcomes and Comparative Effectiveness Research in Oncology

Frank J. Manion, MS, Marcelline R. Harris, PhD, RN, Ayse G. Buyuktur, MPH, MS, Patricia M. Clark, PhDc, RN, Lawrence C. An, MD, and David A. Hanauer, MD, MS

Author information ► Copyright and License information ►

PHARMA CoEpidemiology and Drug Safety 2013; 22: 413–422
Published online 24 February 2013 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3413

ORIGINAL REPORT

Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease

Andrew L. Masica¹, Edward Ewen², Yahya A. Daoud¹, Dunlei Cheng⁶, Nora Franceschini⁵, Rustam E. Kudyakov¹, James R. Bowen², Emily S. Brouwer⁴, Dennis Wallace³, Neil S. Fleming¹ and Suzanne L. West¹,⁵
EHR Data Can help in Risk Prediction Studies

Identifying primary care patients at risk for future diabetes and cardiovascular disease using electronic health records

Marie-France Hivert, Richard W Grant, Peter Shrader and James B Meigs

Received: 21 April 2009 | Accepted: 22 September 2009 | Published: 22 September 2009

Predicting Hospital-Acquired Infections by Scoring System with Simple Parameters

Ying-Jui Chang, Min-Li Yeh, Yu-Chuan Li, Chien-Yeh Hsu, Chao-Cheng Lin, Meng-Shiuan Hsu, Wen-Ta Chiu
Published: August 24, 2011 • https://doi.org/10.1371/journal.pone.0023137
EHR Data along with Biospecimens and Genomic data can aid in Pharmacogenomics studies

**Pharmacogenomics**
(doi:10.2217/pgs.11.164)

**Research Article**

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record

Andrea H Ramirez, Yaping Shi, Jonathan S Schildcrout, Jessica T Delaney, Hua Xu, Matthew T Oetjens, Rebecca L Zuvich, Melissa A Basford, Erica Bowton, Min Jiang, Peter Speltz, Raquel Zink, James Cowan, Jill M Pulley, Marylyn D Ritchie, Daniel R Masys, Dan M Roden, Dana C Crawford & Joshua C Denny*
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality

Hua Xu¹, Melinda C Aldrich²,³, Qingxia Chen⁴,⁵, Hongfang Liu⁶, Neeraja B Peterson⁷, Qi Dai⁸, Mia Levy⁵,⁷, Anushi Shah⁵, Xue Han⁴, Xiaoyang Ruan⁶, Min Jiang¹, Ying Li⁸, Jamii St Julien², Jeremy Warner⁵,⁷, Carol Friedman⁸, Dan M Roden⁷,⁹, Joshua C Denny⁵,⁷
Secondary Use of EHR Timestamp data: Validation and Application for Workflow Optimization

Michelle R. Hribar, PhD,2 Sarah Read-Brown,1 Leah Reznick, MD,1 Lorinna Lombardi, MD,1 Mansi Parikh, MD,1 Thomas R. Yackel, MD, MPH, MS,2 and Michael F. Chiang, MD, MA1,2

Author information ▶ Copyright and License information ▶
If you are requesting identifiable data (PHI/PII) from the DLR, you must do so under:

- A HIPAA Waiver and/or HIPAA Authorization
- Other appropriate documentation

Must be Consistent!
Thanks to:

- Advisory Committee (K. Luzuriaga, C. Kiefe, S. Corvera, M. Koziel, N. Hafer, G. Wolf)
- Clinical Research Task Force (P. Muldoon & M. Koziel Chairs)
- Clinical Trial Management Steering Group (M. Koziel & J Mathew Chairs)
- EPIC Research Integrated Work Group (T. Houston & M. Koziel Chairs)
- UMMHC IT (T. Tarnowski & T. Eglin)
- My Data Science & Technology Team